Sphingolipids and phospholipids in insulin resistance and related metabolic disorders

Nature Reviews Endocrinology

Volumn 13, Issue 2, 2017, Pages 79-91

  Meikle, Peter J ^a   Summers, Scott A ^b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLGLYCEROL; ANTILIPEMIC AGENT; CERAMIDE; CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR; CHOLESTEROL; ELIGLUSTAT; GANGLIOSIDE; GLUCOSYLCERAMIDE; GLYCEROL DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHOLIPID; PLASMALOGEN; S ADENOSYLMETHIONINE; SPHINGOLIPID; SPHINGOMYELIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

CALORIC INTAKE; CARDIOVASCULAR DISEASE; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DISEASE ASSOCIATION; DYSLIPIDEMIA; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; LIPIDOMICS; METABOLIC DISORDER; MOUSE MODEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; PHOSPHOLIPID METABOLISM; PREVALENCE; REVIEW; SPHINGOLIPID METABOLISM; ANIMAL; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC DISEASES; PHOSPHOLIPIDS; SPHINGOLIPIDS;

EID: 84992152164     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2016.169     Document Type: Review

References (153)

1. Danaei, G. et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 378, 31-40 (2011).
2. International Diabetes Federation. IDF Diabetes Atlas 6th edn (International Diabetes Federation, 2013).
3. Ridker, P. M., Mora, S., Rose, L. & Jupiter Trial Study Group. Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. Eur. Heart J. 37, 1373-1379 (2016).
4. Hegele, R. A. et al. Nonstatin low-density lipoprotein-lowering therapy and cardiovascular risk reduction-statement from ATVB council. Arterioscler. Thromb. Vasc. Biol. 35, 2269-2280 (2015).
5. Naci, H., Brugts, J. & Ades, T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circ. Cardiovasc. Qual. Outcomes 6, 390-399 (2013).
6. Navarese, E. P. et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am. J. Cardiol. 111 , 1123-1130 (2013).
7. Dobbins, R. L. et al. The composition of dietary fat directly influences glucose-stimulated insulin secretion in rats. Diabetes 51, 1825-1833 (2002).
8. Stein, D. T. et al. The insulinotropic potency of fatty acids is influenced profoundly by their chain length and degree of saturation. J. Clin. Invest. 100, 398-403 (1997).
9. Brown, M. S. & Goldstein, J. L. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab. 7, 95-96 (2008).
10. Hyötyläinen, T. & Ore ič, M. Optimizing the lipidomics workflow for clinical studies - practical considerations. Anal. Bioanal. Chem. 407, 4973-4993 (2015).
11. Wang, C., Wang, M. & Han, X. Applications of mass spectrometry for cellular lipid analysis. Mol. Biosyst. 11 , 698-713 (2015).
12. Zhao, Y. Y., Wu, S. P., Liu, S., Zhang, Y. & Lin, R. C. Ultra-performance liquid chromatography-mass spectrometry as a sensitive and powerful technology in lipidomic applications. Chem. Biol. Interact. 220, 181-192 (2014).
13. Meikle, P. J., Wong, G., Barlow, C. K. & Kingwell, B. A. Lipidomics: potential role in risk prediction and therapeutic monitoring for diabetes and cardiovascular disease. Pharmacol. Ther. 143, 12-23 (2014).
14. Pietiläinen, K. H. et al. Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic effects - a monozygotic twin study. PLoS ONE 2, e218 (2007).
15. Weir, J. M. et al. Plasma lipid profiling in a large population-based cohort. J. Lipid Res. 54, 2898-2908 (2013).
16. Meikle, P. J. et al. Plasma lipid profiling shows similar associations with prediabetes and type 2 diabetes. PLoS ONE 8, e74341 (2013).
17. Meikle, P. J. et al. Statin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: potential relevance to statin-associated dysglycemia. J. Lipid Res. 56, 2381-2392 (2015).
18. Jove, M. et al. Plasma lipidomics discloses metabolic syndrome with a specific HDL phenotype. FASEB J. 28, 5163-5171 (2014).
19. Holčapek, M. et al. Lipidomic analysis of plasma, erythrocytes and lipoprotein fractions of cardiovascular disease patients using UHPLC/MS, MALDI-MS and multivariate data analysis. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 990, 52-63 (2015).
20. Camont, L. et al. Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities. Arterioscler. Thromb. Vasc. Biol. 33, 2715-2723 (2013).
21. Rached, F. et al. Defective functionality of small, dense HDL3 subpopulations in ST segment elevation myocardial infarction: relevance of enrichment in lysophosphatidylcholine, phosphatidic acid and serum amyloid A. Biochim. Biophys. Acta 1851, 1254-1261 (2015).
22. Rasmiena, A. A., Barlow, C. K., Ng, T. W., Tull, D. & Meikle, P. J. High density lipoprotein efficiently accepts surface but not internal oxidised lipids from oxidised low density lipoprotein. Biochim. Biophys. Acta 1861, 69-77 (2016).
23. Prentki, M. & Madiraju, S. R. Glycerolipid metabolism and signaling in health and disease. Endocr. Rev. 29, 647-676 (2008).
24. Coleman, R. A. & Lee, D. P. Enzymes of triacylglycerol synthesis and their regulation. Prog. Lipid Res. 43, 134-176 (2004).
25. Perry, R. J., Samuel, V. T. , Petersen, K. F. & Shulman, G. I. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 510, 84-91 (2014).
26. Finck, B. N. & Hall, A. M. Does diacylglycerol accumulation in fatty liver disease cause hepatic insulin resistance? Biomed. Res. Int. 2015, 104132 (2015).
27. Cole, L. K., Vance, J. E. & Vance, D. E. Phosphatidylcholine biosynthesis and lipoprotein metabolism. Biochim. Biophys. Acta 1821, 754-761 (2012).
28. Vance, J. E. & Vance, D. E. Phospholipid biosynthesis in mammalian cells. Biochem. Cell Biol. 82, 113-128 (2004).
29. Steenbergen, R. et al. Disruption of the phosphatidylserine decarboxylase gene in mice causes embryonic lethality and mitochondrial defects. J. Biol. Chem. 280, 40032-40040 (2005).
30. Selathurai, A. et al. The CDP-ethanolamine pathway regulates skeletal muscle diacylglycerol content and mitochondrial biogenesis without altering insulin sensitivity. Cell Metab. 21, 718-730 (2015).
31. Arendt, B. M. et al. Nonalcoholic fatty liver disease is associated with lower hepatic and erythrocyte ratios of phosphatidylcholine to phosphatidylethanolamine. Appl. Physiol. Nutr. Metab. 38, 334-340 (2013).
32. Fu, S. et al. Aberrant lipid metabolism disrupts calcium homeostasis causing liver endoplasmic reticulum stress in obesity. Nature 473, 528-531 (2011).
33. Li, Z. et al. The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. Cell Metab. 3, 321-331 (2006).
34. Martínez-Uña, M. et al. Excess S-adenosylmethionine reroutes phosphatidylethanolamine towards phosphatidylcholine and triglyceride synthesis. Hepatology 58, 1296-1305 (2013).
35. Song, J. et al. Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease (NAFLD). FASEB J. 19, 1266-1271 (2005).
36. Dong, H. et al. The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population. J. Hepatol. 46, 915-920 (2007).
37. Hebbard, L. & George, J. Animal models of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 8, 35-44 (2011).
38. Jacobs, R. L., Devlin, C., Tabas, I. & Vance, D. E. Targeted deletion of hepatic CTP:phosphocholine cytidylyltransferase α in mice decreases plasma high density and very low density lipoproteins. J. Biol. Chem. 279, 47402-47410 (2004).
39. Walker, A. K. et al. A conserved SREBP-1/ phosphatidylcholine feedback circuit regulates lipogenesis in metazoans. Cell 147, 840-852 (2011).
40. Jacobs, R. L., van der Veen, J. N. & Vance, D. E. Finding the balance: the role of S-adenosylmethionine and phosphatidylcholine metabolism in development of nonalcoholic fatty liver disease. Hepatology 58, 1207-1209 (2013).
41. Lessig, J. & Fuchs, B. Plasmalogens in biological systems: their role in oxidative processes in biological membranes, their contribution to pathological processes and aging and plasmalogen analysis. Curr. Med. Chem. 16, 2021-2041 (2009).
42. Wallner, S. & Schmitz, G. Plasmalogens the neglected regulatory and scavenging lipid species. Chem. Phys. Lipids 164, 573-589 (2011).
43. Wu, L. C. et al. Purification, identification, and cloning of lysoplasmalogenase, the enzyme that catalyzes hydrolysis of the vinyl ether bond of lysoplasmalogen. J. Biol. Chem. 286, 24916-24930 (2011).
44. Meikle, P. J. et al. Plasma lipidomic analysis of stable and unstable coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 31, 2723-2732 (2011).
45. Goodenowe, D. B. et al. Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia. J. Lipid Res. 48, 2485-2498 (2007).
46. Wood, P. Circulating plasmalogen levels and Alzheimer Disease Assessment Scale-Cognitive scores in Alzheimer patients. J. Psychiatry Neurosci. 35, 59-62 (2010).
47. Mankidy, R. et al. Membrane plasmalogen composition and cellular cholesterol regulation: a structure activity study. Lipids Health Dis. 9, 62 (2010).
48. Maeba, R. et al. Plasmalogens in human serum positively correlate with high-density lipoprotein and decrease with aging. J. Atheroscler. Thromb. 14, 12-18 (2007).
49. Maeba, R. et al. Myo-inositol treatment increases serum plasmalogens and decreases small dense LDL, particularly in hyperlipidemic subjects with metabolic syndrome. J. Nutr. Sci. Vitaminol ( Tokyo) 54, 196-202 (2008).
50. Jürgens, G., Fell, A., Ledinski, G., Chen, Q. & Paltauf, F. Delay of copper-catalyzed oxidation of low density lipoprotein by in vitro enrichment with choline or ethanolamine plasmalogens. Chem. Phys. Lipids 77, 25-31 (1995).
51. Hajimoradi, M., Hassan, Z. M., Pourfathollah, A. A., Daneshmandi, S. & Pakravan, N. The effect of shark liver oil on the tumor infiltrating lymphocytes and cytokine pattern in mice. J. Ethnopharmacol. 126, 565-570 (2009).
52. Wentworth, J. M. et al. GM3 ganglioside and phosphatidylethanolamine-containing lipids are adipose tissue markers of insulin resistance in obese women. Int. J. Obes. (Lond.) 40, 706-713 (2016).
53. Holland, W. L. & Summers, S. A. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr. Rev. 29, 381-402 (2008).
54. Holland, W. L. et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab. 5, 167-179 (2007).
55. Park, T. S. et al. Modulation of lipoprotein metabolism by inhibition of sphingomyelin synthesis in ApoE knockout mice. Atherosclerosis 189, 264-272 (2006).
56. Hojjati, M. R. et al. Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. J. Biol. Chem. 280, 10284-10289 (2005).
57. Park, T. S. et al. Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J. Lipid Res. 49, 2101-2112 (2008).
58. Eichler, F. S. et al. Overexpression of the wild-type SPT1 subunit lowers desoxysphingolipid levels and rescues the phenotype of HSAN1. J. Neurosci. 29, 14646-14651 (2009).
59. Bertea, M. et al. Deoxysphingoid bases as plasma markers in diabetes mellitus. Lipids Health Dis. 9, 84 (2010).
60. Othman, A. et al. Plasma deoxysphingolipids: a novel class of biomarkers for the metabolic syndrome? Diabetologia 55, 421-431 (2012).
61. Zuellig, R. A. et al. Deoxysphingolipids, novel biomarkers for type 2 diabetes, are cytotoxic for insulin-producing cells. Diabetes 63, 1326-1339 (2014).
62. Othman, A. et al. Fenofibrate lowers atypical sphingolipids in plasma of dyslipidemic patients: a novel approach for treating diabetic neuropathy? J. Clin. Lipidol. 9, 568-575 (2015).
63. Chaurasia, B. & Summers, S. A. Ceramides - lipotoxic inducers of metabolic disorders. Trends Endocrinol. Metab. 26, 538-550 (2015).
64. Chavez, J. A. et al. A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids. J. Biol. Chem. 278, 10297-10303 (2003).
65. Stratford, S., DeWald, D. B. & Summers, S. A. Ceramide dissociates 3′-phosphoinositide production from pleckstrin homology domain translocation. Biochem. J. 354, 359-368 (2001).
66. Summers, S. A., Garza, L. A., Zhou, H. & Birnbaum, M. J. Regulation of insulin-stimulated glucose transporter GLUT4 translocation and Akt kinase activity by ceramide. Mol. Cell. Biol. 18, 5457-5464 (1998).
67. Chavez, J. A. et al. Ceramides and glucosylceramides are independent antagonists of insulin signaling. J. Biol. Chem. 289, 723-734 (2014).
68. Zhang, Q. J. et al. Ceramide mediates vascular dysfunction in diet-induced obesity by PP2A-mediated dephosphorylation of the eNOS-Akt complex. Diabetes 61, 1848-1859 (2012).
69. Bikman, B. T. et al. Fenretinide prevents lipid-induced insulin resistance by blocking ceramide biosynthesis. J. Biol. Chem. 287, 17426-17437 (2012).
70. Chun, L. et al. Inhibition of ceramide synthesis reverses endothelial dysfunction and atherosclerosis in streptozotocin-induced diabetic rats. Diabetes Res. Clin. Pract. 93, 77-85 (2011).
71. Park, T. S., Rosebury, W., Kindt, E. K., Kowala, M. C. & Panek, R. L. Serine palmitoyltransferase inhibitor myriocin induces the regression of atherosclerotic plaques in hyperlipidemic ApoE-deficient mice. Pharmacol. Res. 58, 45-51 (2008).
72. Glaros, E. N. et al. Myriocin slows the progression of established atherosclerotic lesions in apolipoprotein E gene knockout mice. J. Lipid Res. 49, 324-331 (2008).
73. Glaros, E. N. et al. Inhibition of atherosclerosis by the serine palmitoyl transferase inhibitor myriocin is associated with reduced plasma glycosphingolipid concentration. Biochem. Pharmacol. 73, 1340-1346 (2007).
74. Park, T. S. & Goldberg, I. J. Sphingolipids, lipotoxic cardiomyopathy, and cardiac failure. Heart Fail. Clin. 8, 633-641 (2012).
75. Jiang, X. C., Goldberg, I. J. & Park, T. S. Sphingolipids and cardiovascular diseases: lipoprotein metabolism, atherosclerosis and cardiomyopathy. Adv. Exp. Med. Biol. 721, 19-39 (2011).
76. Holland, W. L. et al. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab. 17, 790-797 (2013).
77. Holland, W. L. et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat. Med. 17, 55-63 (2011).
78. Lopez, X., Goldfine, A. B., Holland, W. L., Gordillo, R. & Scherer, P. E. Plasma ceramides are elevated in female children and adolescents with type 2 diabetes. J. Pediatr. Endocrinol. Metab. 26, 995-998 (2013).
79. Haus, J. M. et al. Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. Diabetes 58, 337-343 (2009).
80. Warshauer, J. T. et al. Effect of pioglitazone on plasma ceramides in adults with metabolic syndrome. Diabetes Metab. Res. Rev. 31, 734-744 (2015).
81. Bergman, B. C. et al. Serum sphingolipids: relationships to insulin sensitivity and changes with exercise in humans. Am. J. Physiol. Endocrinol. Metab. 309, E398-E408 (2015).
82. Amati, F. et al. Skeletal muscle triglycerides, diacylglycerols, and ceramides in insulin resistance: another paradox in endurance-trained athletes? Diabetes 60, 2588-2597 (2011).
83. Coen, P. M. et al. Reduced skeletal muscle oxidative capacity and elevated ceramide but not diacylglycerol content in severe obesity. Obesity (Silver Spring) 21, 2362-2371 (2013).
84. de la Maza, M. P. et al. Skeletal muscle ceramide species in men with abdominal obesity. J. Nutr. Health Aging 19, 389-396 (2015).
85. Coen, P. M. et al. Insulin resistance is associated with higher intramyocellular triglycerides in type I but not type II myocytes concomitant with higher ceramide content. Diabetes 59, 80-88 (2010).
86. Adams, J. M. et al. Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 53, 25-31 (2004).
87. Skovbro, M. et al. Human skeletal muscle ceramide content is not a major factor in muscle insulin sensitivity. Diabetologia 51, 1253-1260 (2008).
88. Petersen, M. C. & Jurczak, M. J. CrossTalk opposing view: intramyocellular ceramide accumulation does not modulate insulin resistance. J. Physiol. 594, 3171-3174 (2016).
89. Summers, S. A. & Goodpaster, B. H. CrossTalk proposal: intramyocellular ceramide accumulation does modulate insulin resistance. J. Physiol. 594, 3167-3170 (2016).
90. 16:0 ceramide production promotes weight gain and glucose intolerance. Cell Metab. 20, 678-686 (2014).
91. Raichur, S. et al. CerS2 haploinsufficiency inhibits β-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance. Cell Metab. 20, 687-695 (2014).
92. Hla, T. & Kolesnick, R. C16:0-ceramide signals insulin resistance. Cell Metab. 20, 703-705 (2014).
93. 16:0-ceramide pools and contributes to the development of diet-induced obesity. J. Biol. Chem. 291, 6989-7003 (2016).
94. Luukkonen, P. K. et al. Hepatic ceramides dissociate steatosis and insulin resistance in patients with nonalcoholic fatty liver disease. J. Hepatol. 64, 1167-1175 (2016).
95. Bergman, B. C. et al. Muscle sphingolipids during rest and exercise: a C18:0 signature for insulin resistance in humans. Diabetologia 59, 785-798 (2016).
96. Hanamatsu, H. et al. Altered levels of serum sphingomyelin and ceramide containing distinct acyl chains in young obese adults. Nutr. Diabetes 4, e141 (2014).
97. Martinez-Ramirez, M. et al. HDL-sphingomyelin reduction after weight loss by an energy-restricted diet is associated with the improvement of lipid profile, blood pressure, and decrease of insulin resistance in overweight/obese patients. Clin. Chim. Acta 454, 77-81 (2016).
98. Li, Z. et al. Reducing plasma membrane sphingomyelin increases insulin sensitivity. Mol. Cell. Biol. 31, 4205-4218 (2011).
99. Sugimoto, M. et al. Characterization of the role of sphingomyelin synthase 2 in glucose metabolism in whole-body and peripheral tissues in mice. Biochim. Biophys. Acta 1861, 688-702 (2016).
100. Fan, Y. et al. Selective reduction in the sphingomyelin content of atherogenic lipoproteins inhibits their retention in murine aortas and the subsequent development of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 30, 2114-2120 (2010).
101. Aerts, J. M. et al. Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity. Diabetes 56, 1341-1349 (2007).
102. Zhao, H. et al. Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes. Diabetes 56, 1210-1218 (2007).
103. Zhao, H. et al. Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice. Hepatology 50, 85-93 (2009).
104. -/- mice and rabbits fed a high-fat and -cholesterol diet. Circulation 129, 2403-2413 (2014).
105. Bietrix, F. et al. Inhibition of glycosphingolipid synthesis induces a profound reduction of plasma cholesterol and inhibits atherosclerosis development in APOE∗3 Leiden and low-density lipoprotein receptor-/- mice. Arterioscler. Thromb. Vasc. Biol. 30, 931-937 (2010).
106. Glaros, E. N., Kim, W. S., Rye, K. A., Shayman, J. A. & Garner, B. Reduction of plasma glycosphingolipid levels has no impact on atherosclerosis in apolipoprotein E-null mice. J. Lipid Res. 49, 1677-1681 (2008).
107. Inokuchi, J. Insulin resistance as a membrane microdomain disorder. Yakugaku Zasshi 127, 579-586 (2007).
108. Tagami, S. et al. Ganglioside GM3 participates in the pathological conditions of insulin resistance. J. Biol. Chem. 277, 3085-3092 (2002).
109. Yamashita, T. et al. Enhanced insulin sensitivity in mice lacking ganglioside GM3. Proc. Natl Acad. Sci. USA 100, 3445-3449 (2003).
110. Ussher, J. R. et al. Inhibition of de novo ceramide synthesis reverses diet-induced insulin resistance and enhances whole-body oxygen consumption. Diabetes 59, 2453-2464 (2010).
111. Murphy, M. P. Mitochondrial dysfunction indirectly elevates ROS production by the endoplasmic reticulum. Cell Metab. 18, 145-146 (2013).
112. de Mello, V. D. et al. Link between plasma ceramides, inflammation and insulin resistance: association with serum IL-6 concentration in patients with coronary heart disease. Diabetologia 52, 2612-2615 (2009).
113. Majumdar, I. & Mastrandrea, L. D. Serum sphingolipids and inflammatory mediators in adolescents at risk for metabolic syndrome. Endocrine 41, 442-449 (2012).
114. Caballero, F. et al. Specific contribution of methionine and choline in nutritional nonalcoholic steatohepatitis: impact on mitochondrial S-adenosyl-l-methionine and glutathione. J. Biol. Chem. 285, 18528-18536 (2010).
115. Mato, J. M. & Lu, S. C. Role of S-adenosyl-l-methionine in liver health and injury. Hepatology 45, 1306-1312 (2007).
116. Cano, A. et al. Methionine adenosyltransferase 1A gene deletion disrupts hepatic very low-density lipoprotein assembly in mice. Hepatology 54, 1975-1986 (2011).
117. Moylan, C. A. et al. Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease. Hepatology 59, 471-482 (2014).
118. Brites, P. et al. Alkyl-glycerol rescues plasmalogen levels and pathology of ether-phospholipid deficient mice. PLoS ONE 6, e28539 (2011).
119. Das, A. K., Holmes, R. D., Wilson, G. N. & Hajra, A. K. Dietary ether lipid incorporation into tissue plasmalogens of humans and rodents. Lipids 27, 401-405 (1992).
120. Marigny, K. et al. Modulation of endothelial permeability by 1-O-alkylglycerols. Acta Physiol. Scand. 176, 263-268 (2002).
121. Pédrono, F., Saïag, B., Moulinoux, J. P. & Legrand, A. B. 1-O-alkylglycerols reduce the stimulating effects of bFGF on endothelial cell proliferation in vitro. Cancer Lett. 251, 317-322 (2007).
122. Zhang, M., Sun, S., Tang, N., Cai, W. & Qian, L. Oral administration of alkylglycerols differentially modulates high-fat diet-induced obesity and insulin resistance in mice. Evid. Based Complement. Alternat. Med. 2013, 834027 (2013).
123. Rasmiena, A. A. et al. Plasmalogen modulation attenuates atherosclerosis in ApoE- and ApoE/ GPx1-deficient mice. Atherosclerosis 243, 598-608 (2015).
124. Iannitti, T. & Palmieri, B. An update on the therapeutic role of alkylglycerols. Mar. Drugs 8, 2267-2300 (2010).
125. Wood, P. L., Khan, M. A., Mankidy, R., Smith, T. & Goodenowe, D. B. in Alzheimer's Disease Pathogenesis-Core Concepts, Shifting Paradigms and Therapeutic Targets Ch. 24 (ed. De La Monte, S.) 561-588 (InTech, 2011).
126. Wood, P. L. et al. Oral bioavailability of the ether lipid plasmalogen precursor, PPI-1011, in the rabbit: a new therapeutic strategy for Alzheimer's disease. Lipids Health Dis. 10, 227 (2011).
127. Grégoire, L. et al. Plasmalogen precursor analog treatment reduces levodopa-induced dyskinesias in parkinsonian monkeys. Behav. Brain Res. 286, 328-337 (2015).
128. Miville-Godbout, E. et al. Plasmalogen augmentation reverses striatal dopamine loss in MPTP mice. PLoS ONE 11 , e0151020 (2016).
129. Kien, C. L. et al. A lipidomics analysis of the relationship between dietary fatty acid composition and insulin sensitivity in young adults. Diabetes 62, 1054-1063 (2013).
130. Lankinen, M. et al. A healthy nordic diet alters the plasma lipidomic profile in adults with features of metabolic syndrome in a multicenter randomized dietary intervention. J. Nutr. 146, 662-672 (2016).
131. Coen, P. M. et al. Exercise and weight loss improve muscle mitochondrial respiration, lipid partitioning, and insulin sensitivity after gastric bypass surgery. Diabetes 64, 3737-3750 (2015).
132. Bikman, B. T. & Summers, S. A. Ceramides as modulators of cellular and whole-body metabolism. J. Clin. Invest. 121, 4222-4230 (2011).
133. Chavez, J. A. & Summers, S. A. A ceramide-centric view of insulin resistance. Cell Metab. 15, 585-594 (2012).
134. Wang, S. et al. Simultaneous determination of nucleosides, myriocin, and carbohydrates in Cordyceps by HPLC coupled with diode array detection and evaporative light scattering detection. J. Sep. Sci. 32, 4069-4076 (2009).
135. Yu, J., Xu, H., Mo, Z., Zhu, H. & Mao, X. Determination of myriocin in natural and cultured Cordyceps cicadae using 9-fluorenylmethyl chloroformate derivatization and high-performance liquid chromatography with UV-detection. Anal. Sci. 25, 855-859 (2009).
136. Yu, S. H. et al. Hypoglycemic activity through a novel combination of fruiting body and mycelia of Cordyceps militaris in high-fat diet-induced type 2 diabetes mellitus mice. J. Diabetes Res. 2015, 723190 (2015).
137. Dong, Y. et al. Studies on the antidiabetic activities of Cordyceps militaris extract in diet-streptozotocin-induced diabetic Sprague-Dawley rats. Biomed. Res. Int. 2014, 160980 (2014).
138. Zhang, H. W. et al. Cordyceps sinensis (a traditional Chinese medicine) for treating chronic kidney disease. Cochrane Database Syst. Rev. 12, CD008353 (2014).
139. Mody, N. & McIlroy, G. D. The mechanisms of fenretinide-mediated anti-cancer activity and prevention of obesity and type-2 diabetes. Biochem. Pharmacol. 91, 277-286 (2014).
140. Siddique, M. M., Li, Y., Chaurasia, B., Kaddai, V. A. & Summers, S. A. Dihydroceramides: from bit players to lead actors. J. Biol. Chem. 290, 15371-15379 (2015).
141. Veronesi, U. et al. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann. Oncol. 17, 1065-1071 (2006).
142. Zanardi, S. et al. Clinical trials with retinoids for breast cancer chemoprevention. Endocr. Relat. Cancer 13, 51-68 (2006).
143. Sabichi, A. L. et al. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin. Cancer Res. 14, 224-229 (2008).
144. Aerts, J. M. et al. Glycosphingolipids and insulin resistance. Adv. Exp. Med. Biol. 721, 99-119 (2011).
145. Bennett, L. L. & Turcotte, K. Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease. Drug Des. Devel. Ther. 9, 4639-4647 (2015).
146. Shayman, J. A. Developing novel chemical entities for the treatment of lysosomal storage disorders: an academic perspective. Am. J. Physiol. Renal Physiol. 309, F996-F999 (2015).
147. Shayman, J. A. The design and clinical development of inhibitors of glycosphingolipid synthesis: will invention be the mother of necessity? Trans. Am. Clin. Climatol. Assoc. 124, 46-60 (2013).
148. Yang, G. et al. Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome. Am. J. Physiol. Endocrinol. Metab. 297, E211-E224 (2009).
149. Kurek, K. et al. Inhibition of ceramide de novo synthesis ameliorates diet induced skeletal muscles insulin resistance. J. Diabetes Res. 2015, 154762 (2015).
150. Dekker, M. J. et al. Inhibition of sphingolipid synthesis improves dyslipidemia in the diet-induced hamster model of insulin resistance: evidence for the role of sphingosine and sphinganine in hepatic VLDL-apoB100 overproduction. Atherosclerosis 228, 98-109 (2013).
151. Chakraborty, M. et al. Myeloid cell-specific serine palmitoyltransferase subunit 2 haploinsufficiency reduces murine atherosclerosis. J. Clin. Invest. 123, 1784-1797 (2013).
152. Kasumov, T. et al. Ceramide as a mediator of nonalcoholic fatty liver disease and associated atherosclerosis. PLoS ONE 10, e0126910 (2015).
153. Kurek, K. et al. Inhibition of ceramide de novo synthesis reduces liver lipid accumulation in rats with nonalcoholic fatty liver disease. Liver Int. 34, 1074-1083 (2014).